Showing results (361-370 of 376) with videos related to
Sort By:
Pageof 38
Plos One|January 27, 2026
RUBCN as a novel prognostic biomarker and therapeutic target in breast cancerDong Dong Yang, Cheng Hao Liu, Sheng Qiu Jia, et al.Proceedings of the National Academy of Sciences of the United States of America|November 24, 2021
BAP1 forms a trimer with HMGB1 and HDAC1 that modulates gene × environment interaction with asbestosFlavia Novelli, Angela Bononi, Qian Wang, et al.Proceedings of the National Academy of Sciences of the United States of America|September 20, 2023
HMGB1 released by mesothelial cells drives the development of asbestos-induced mesotheliomaJoelle S Suarez, Flavia Novelli, Keisuke Goto, et al.Proceedings of the National Academy of Sciences of the United States of America|December 15, 2020
Heterozygous germline BLM mutations increase susceptibility to asbestos and mesotheliomaAngela Bononi, Keisuke Goto, Guntulu Ak, et al.Alimentary Pharmacology & Therapeutics|July 14, 2020
Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's diseaseMatthew Bohm, Ronghui Xu, Yiran Zhang, et al.Proceedings of the National Academy of Sciences of the United States of America|January 19, 2023
BAP1 is a novel regulator of HIF-1αAngela Bononi, Qian Wang, Alicia A Zolondick, et al.Journal of Controlled Release : Official Journal of the Controlled Release Society|February 6, 2026
ApoE-directed CpG nano-immunoadjuvant ameliorates Alzheimer's-like pathology in miceXin Huang, Yan-Yun Sun, Yi-Ren Qin, et al.International Journal of Radiation Oncology, Biology, Physics|January 28, 2017
Bone Marrow-sparing Intensity Modulated Radiation Therapy With Concurrent Cisplatin For Stage IB-IVA Cervical Cancer: An International Multicenter Phase II Clinical Trial (INTERTECC-2)Loren K Mell, Igor Sirák, Lichun Wei, et al.JAMA|February 8, 2018
Prevalence of Fetal Alcohol Spectrum Disorders in 4 US CommunitiesPhilip A May, Christina D Chambers, Wendy O Kalberg, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 11, 2020
Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative ColitisDana Lukin, David Faleck, Ronghui Xu, et al.Pageof 38